A randomized dowble-blind trial comparing a two-component acellular to a whole-cell pertussis vaaccine in Senegal

Vaccine

Volumn 15, Issue 15, 1997, Pages 1606-1612

  Simondon, François ^a,b   Preziosi, Marie Pierre ^a   Yam, Ablaye ^a   Kane, Coumba Toure ^c   Chabirand, Laurence ^a   Iteman, Isabelle ^d   Sanden, Gary ^e   Mboup, Souleymane ^c   Hoffenbach, Agnes ^f   Knudsen, Kim ^g   Guiso, Nicole ^d   Wassilak, Steven ^h   Cadoz, Michel ^f  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d INSTITUT PASTEUR   (France)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Pasteur Merieux Serums et Vaccins ^*  (France)

^g Epidemiology Research Unit   (Denmark)

^h CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

Acellular vaccine; Africa; Clinical trial; Pertussis; Vaccine efficacy; Whole cell vaccine

Indexed keywords

PERTUSSIS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VACCINATION; ADULT; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; MALE;

ADULT; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALE;

EID: 0030613642     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00100-X     Document Type: Article

References (28)

1. Fine, P.E.M. and Clarkson, J.A. Reflections on the efficacy of pertussis vaccines. Review of Infectious Diseases 1987, 9, 866-883.
2. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo controlled trial of two acellular vaccines in Sweden-protective efficacy and adverse events. Lancet 1988, 1, 955-960 [erratum, Lancet 1988, 1, 1238].
3. Storsaeter, J. and Olin, P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992, 10, 142-144.
4. Simondon, F., Yam, A., Gagnepain, J.Y., Wassilak, S., Danve, B. and Cadoz, M. Comparative study of the safety and immunogenicity of a DT-acellular pertussis and a DT-Whole-cell pertussis vaccine in Senegalese infants. European Journal of Clinical Microbiology and Infectious Diseases 1996, 15, 927-932.
5. Edwards, K.M., Meade, B.D. and Decker, M.D. et al. Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 1995, 96, (suppl), 548-557.
6. Preziosi, M.P., Wassilak, S., Yam, A., Ndiaye, M., Simaga, A. and Simondon, F. Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. New England Journal of Medicine 336, 5, 370-373.
7. Regan, J. and Lowe, F. Enrichment medium for the isolation of Bordetella. Journal of Clinical Microbiology 1977, 6, 303-309.
8. Manclark, C.R., Meade, B.D. and Burstyn, D.G. Serological response to Bordetella pertussis. In: Manual of Clinical Laboratory Immunology, 3rd edition (Eds Rose, N.R., Friedman, H. and Fahey, J.L.). American Society for Microbiology, Washington, DC, 1986, pp. 388-394.
9. Grimprel, E., Bègué, P., Anjak, I. and Guiso, N. Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection. Journal of Clinical Microbiology 1993, 31, 2745-2750.
10. Reizenstein, E. Diagnostic polymerase chain reaction. Proceedings of the International Symposium on Pertussis Vaccine Trials, 30 October-1 November 1995, in press.
11. WHO Meeting on Case Definition of Pertussis, Geneva, 10-11 January 1991. World Health Organization, Geneva, 1991, pp. 4-5 (issue no. MIN/EPI/PERT/91.1).
12. Breslow, N.E. and Day, N.E. Statistical methods in cancer research: Vol 2. The design and analysis of cohort studies. IARC Scientific Publication no. 82, International Agency for Research on Cancer, Lyon, France, 1987
13. Rothman, K.J. Modern Epidemiology. Little, Brown and Company, Boston/Toronto, 1986.
14. SAS version 6.10. Statistical Analysis Systems Institute Inc., Cary, NC, USA.
15. EPI Info version 6, CDC, Atlanta, 1994.
16. Decker, M.D., Edwards, K.M. and Steinhoff, M.C. et al. Comparison of 13 acellular vaccines: adverse reactions. Pediatrics 1995, 96, (suppl), 557-566.
17. David, T. and Groupe de Pédiatres de la Région Lyonnaise, Cadoz, M. Acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated polio vaccine (AcPDT IPV): comparison to a DTP-IPV with a whole-cell vaccine component (WcPDT IPV) in infants. 31st Annual ICAAC Meeting 1991, 60, 108 (abstr.).
18. Blackwelder, W.C., Storsaeter, J., Olin, P. and Hallander, H.O. Pertussis vaccines. Efficacy and evaluation of clinical case definitions. AJDC 1991, 145, 1285-1289.
19. Orenstein, W.A., Bernier, R.H., Dondero, T.J., Hinman, A.R., Marks, J.S., Bart, K.J. and Sirotkin, B. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization 1985, 63, 1055-1068.
20. Baron, S., Begue, P. and Desenclos, J.C. et al. Evaluation épidémiologique, clinique et biologique de la coqueluche en France. BEH 1995, 19, 83-85.
21. Swartz, A., Roumianttzeff, M. and Peyron, L. et al. Use of a combined DTP-Polio vaccine in a reduced schedule. Developments in Biological Standardization 1986, 65, 159-166.
22. Trollfors, B., Taranger, J. and Lagergard, T. et al. A placebo controlled trial of a pertussis toxoid vaccine. New England Journal of Medicine 1995, 333, 1045-1050.
23. Greco, D., Salmoso, S. and Mastrantonio, P. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine 1996, 334, 341-348.
24. Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine 1996, 334, 349-355.
25. Schmitt, H.J., von Konig, C.H.W, and Neiss, A. et al. Efficacy of acellular pertussis vaccine in early childhood after house-hold exposure. JAMA 1996, 275, 37-41.
26. International Symposium on Pertussis Vacine Trials, Rome, 30 October-1 November 1995: trial synopses. Instituto Superiore di Sanita, Rome, 1995
27. Edwards, K.M. and Decker, M.D. Acellular pertussis vaccines for infants. New England Journal of Medicine 1996, 334, 391-392.
28. Steinhoff, M.C., Reed, G.F. and Decker, M.D. et al. A randomized comparison of reactogenicily and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995, 96, (suppl), 567-570.